PDX Breast Cancer Model WHIM17

Technical Information
Published in Cell Reports, WHIM17 is a highly characterized, triple negative (HER2-, ER-, PR-) PDX model of breast cancer, derived from the primary tumor.

Technical Data

Whole Genome Sequenced
No
RNA Sequence
Yes

Tumor Information

Availability
Available
Tumor Site
Primary: Breast
Patient Number
17

Patient Demographics

Age at Diagnosis
64
Patient Race
Caucasian
Family History
Possible paternal grandmother

PAM50 Subtype

PAM50 Originating Tumor
N/A
PAM50 Early Passage
Basal
PAM50 Late Passage
Basal

Genotype/Mutations

ER Status
Negative
PR Status
Negative
HER2 Status
Negative
p53 Genotype
WT
PIK3CA Genotype
WT
ESR1 Genotype
WT
Phosphoprotein Highest Rank
PKC-delta_pS664

Pathology

Specimen Type
Core -- breast primary
Clinical Stage, Diagnosis
2B
Pathological Stage
PathCR
Sample Stage
2B
Pathology
Ductal
Tumor Grade
3
Systemic Treatments
Grafted sample for WHIM17; neoadjuvant paclitaxel followed by Adriamycin, Cyclophosphomide; adjuvant radiation to right chest wall
Overall Survival (months)
37

PAM50 Subtype Expression

PAM50 Microarray Validation
PDX Breast Cancer Model WHIM17 - PAM50 Microarray Validation
Validation of PAM50 microarray. Coclustering of 250 human breast samples representing all the PAM50 intrinsic subtypes and 22 HIM models using the 50 PAM50 genes. Gene expression data of all samples has been obtained using 244K Agilent microarrays.
Claudin Low Signature
PDX Breast Cancer Model WHIM17 - Claudin Low Signature
Microarray of 807 genes that make up the Claudin-low signature. On the right, the expression of each gene (up- or downregulated) of the Claudin-low signature is shown. The two Claudin-low samples (WHIM12 and WHIM17) are identified below the array tree.

Circos Plots & Phosphoprotein Expression

Phosphoprotein Expression
PDX Breast Cancer Model WHIM17 - Phosphoprotein Expression
Phosphoprotein expression by RPPA. The RPPA data for WHIM samples and 386 TCGA samples were combined after standardizing the data for each marker (i.e., subtracting the mean and then divided by the standard deviation) in the separate data sets. The combined samples were hierarchically clustered using a Pearson correlation based distance matrix ((1-rho)/2, where rho is the Pearson correlation matrix) and the “ward” linkage based on Ward’s minimum variance. In every case the samples from each WHIM line clustered adjacently, including the two double PDX model isolations (WHIM2 and WHIM5, WHIM20 and WHIM23). This demonstrates that intra-PDX heterogeneity was considerably less than the inter-tumoral heterogeneity in a large RPPA data set and was relatively stable over time and passage.
Protocols & Documents
Reviews

Write Your Own Review

You're reviewing: PDX Breast Cancer Model WHIM17

How do you rate this product? *

 
1 1 star
2 2 star
3 3 star
4 4 star
5 5 star
Value
Quality
Price
Back to top